{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T02:22:40Z","timestamp":1788056560941,"version":"build-2784847793"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T00:00:00Z","timestamp":1695686400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T00:00:00Z","timestamp":1695686400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1007\/s00277-023-05446-5","type":"journal-article","created":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T02:01:37Z","timestamp":1695693697000},"page":"2207-2213","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Role of brentuximab vedotin plus sirolimus in the treatment of classical Hodgkin lymphoma type post-transplant lymphoproliferative disorder: a case-based review"],"prefix":"10.1007","volume":"103","author":[{"given":"Kuangguo","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duanhao","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunfeng","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6959-7077","authenticated-orcid":false,"given":"Wei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,26]]},"reference":[{"issue":"6","key":"5446_CR1","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1056\/NEJMra1702693","volume":"378","author":"D Dierickx","year":"2018","unstructured":"Dierickx D, Habermann TM (2018) Post-transplantation lymphoproliferative disorders in adults. New Eng J Med 378(6):549\u2013562","journal-title":"New Eng J Med"},{"issue":"5","key":"5446_CR2","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1111\/j.1399-0012.2011.01593.x","volume":"26","author":"TS Chan","year":"2012","unstructured":"Chan TS, Hwang YY, Gill H, Au WY, Leung AY, Tse E, Chim CS, Loong F, Kwong YL (2012) Post-transplant lymphoproliferative diseases in Asian solid organ transplant recipients: late onset and favorable response to treatment. Clin Trans 26(5):679\u2013683","journal-title":"Clin Trans"},{"key":"5446_CR3","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.anndiagpath.2018.09.011","volume":"37","author":"SM Choi","year":"2018","unstructured":"Choi SM, O\u2019Malley DP (2018) Diagnostically relevant updates to the 2017 WHO classification of lymphoid neoplasms. Ann Diagn Pathol 37:67\u201374","journal-title":"Ann Diagn Pathol"},{"issue":"6","key":"5446_CR4","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1002\/ajh.24346","volume":"91","author":"AS Rosenberg","year":"2016","unstructured":"Rosenberg AS, Klein AK, Ruthazer R, Evens AM (2016) Hodgkin lymphoma post-transplant lymphoproliferative disorder: a comparative analysis of clinical characteristics, prognosis, and survival. Amer J Hematol 91(6):560\u2013565","journal-title":"Amer J Hematol"},{"issue":"18","key":"5446_CR5","doi-asserted-by":"publisher","first-page":"6565","DOI":"10.1002\/cam4.3298","volume":"9","author":"MPE Andr\u00e9","year":"2020","unstructured":"Andr\u00e9 MPE, Carde P, Viviani S, Bellei M, Fortpied C, Hutchings M, Gianni AM, Brice P, Casasnovas O, Gobbi PG, Zinzani PL, Dupuis J, Iannitto E, Rambaldi A, Bri\u00e8re J, Cl\u00e9ment-Filliatre L, Heczko M, Valagussa P, Douxfils J, Depaus J, Federico M, Mounier N (2020) Long-term overall survival and toxicities of ABVD vs BEACOPP in advanced Hodgkin lymphoma: a pooled analysis of four randomized trials. Cancer Med 9(18):6565\u20136575","journal-title":"Cancer Med"},{"issue":"4","key":"5446_CR6","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1056\/NEJMoa1708984","volume":"378","author":"JM Connors","year":"2018","unstructured":"Connors JM, Jurczak W, Straus DJ, Ansell SM, Kim WS, Gallamini A, Younes A, Alekseev S, Illes A, Picardi M, Lech-Maranda E, Oki Y, Feldman T, Smolewski P, Savage KJ, Bartlett NL, Walewski J, Chen R, Ramchandren R, Zinzani PL, Cunningham D, Rosta A, Josephson NC, Song E, Sachs J, Liu R, Jolin HA, Huebner D, Radford J, Grp EC-S (2018) Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin\u2019s lymphoma. New Eng J Med 378(4):331\u2013344","journal-title":"New Eng J Med"},{"issue":"18","key":"5446_CR7","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","volume":"30","author":"A Younes","year":"2012","unstructured":"Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, Ramchandren R, Bartlett NL, Cheson BD, de Vos S, Forero-Torres A, Moskowitz CH, Connors JM, Engert A, Larsen EK, Kennedy DA, Sievers EL, Chen R (2012) Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin\u2019s lymphoma. J Cli Oncol 30(18):2183\u20132189","journal-title":"J Cli Oncol"},{"issue":"4","key":"5446_CR8","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1411087","volume":"372","author":"SM Ansell","year":"2015","unstructured":"Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, Schuster SJ, Millenson MM, Cattry D, Freeman GJ, Rodig SJ, Chapuy B, Ligon AH, Zhu L, Grosso JF, Kim SY, Timmerman JM, Shipp MA, Armand P (2015) PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma. New Eng J Med 372(4):311\u2013319","journal-title":"New Eng J Med"},{"issue":"10","key":"5446_CR9","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1517\/14728220903196779","volume":"13","author":"H Adams","year":"2009","unstructured":"Adams H, Campidelli C, Dirnhofer S, Pileri SA, Tzankov A (2009) Clinical, phenotypic and genetic similarities and disparities between post-transplant and classical Hodgkin lymphomas with respect to therapeutic targets. Expert Opin Ther Targets 13(10):1137\u20131145","journal-title":"Expert Opin Ther Targets"},{"issue":"6","key":"5446_CR10","doi-asserted-by":"publisher","first-page":"e1008590","DOI":"10.1371\/journal.ppat.1008590","volume":"16","author":"C Li","year":"2020","unstructured":"Li C, Romero-Masters JC, Huebner S, Ohashi M, Hayes M, Bristol JA, Nelson SE, Eichelberg MR, Van Sciver N, Ranheim EA, Scott RS, Johannsen EC, Kenney SC (2020) EBNA2-deleted Epstein-Barr virus (EBV) isolate, P3HR1, causes Hodgkin-like lymphomas and diffuse large B cell lymphomas with type II and Wp-restricted latency types in humanized mice. PLoS Pathog 16(6):e1008590","journal-title":"PLoS Pathog"},{"issue":"1","key":"5446_CR11","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1046\/j.1397-3142.2003.00142.x","volume":"8","author":"S Ranganathan","year":"2004","unstructured":"Ranganathan S, Jaffe R (2004) Is there a difference between Hodgkin\u2019s disease and a Hodgkin\u2019s-like post-transplant lymphoproliferative disorder, and why should that be of any interest? Pediatr Trans 8(1):6\u20138","journal-title":"Pediatr Trans"},{"issue":"6","key":"5446_CR12","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1080\/0284186X.2020.1731924","volume":"59","author":"A Kinch","year":"2020","unstructured":"Kinch A, Amini RM, Hollander P, Molin D, Sundstr\u00f6m C, Enblad G (2020) CD30 expression and survival in posttransplant lymphoproliferative disorders. Acta Oncol 59(6):673\u2013680","journal-title":"Acta Oncol"},{"issue":"6","key":"5446_CR13","doi-asserted-by":"publisher","first-page":"5067","DOI":"10.3390\/curroncol28060426","volume":"28","author":"J Hong","year":"2021","unstructured":"Hong J, Johnson WT, Kartan S, Gonsalves AS, Fenkel JM, Gong JZ, Porcu P (2021) Durable response to brentuximab vedotin plus cyclophosphamide, doxorubicin, and prednisone (BV-CHP) in a patient with CD30-positive PTCL arising as a post-transplant lymphoproliferative disorder (PTLD). Current oncology (Toronto, Ont) 28(6):5067\u20135072","journal-title":"Current oncology (Toronto, Ont)"},{"key":"5446_CR14","doi-asserted-by":"publisher","first-page":"295","DOI":"10.3389\/fmed.2019.00295","volume":"6","author":"T Mika","year":"2019","unstructured":"Mika T, Strate K, Ladigan S, Aigner C, Schlegel U, Tischoff I, Tischer-Zimmermann S, Eiz-Vesper B, Maecker-Kolhoff B, Schroers R (2019) Refractory Epstein-Barr Virus (EBV)-related post-transplant lymphoproliferative disease: cure by combined brentuximab vedotin and allogeneic EBV-specific T-lymphocytes. Front Med 6:295","journal-title":"Front Med"},{"key":"5446_CR15","first-page":"572","volume":"98","author":"W Zinke-Cerwenka","year":"2013","unstructured":"Zinke-Cerwenka W, Troppan K, Beham-Schmid C, Pucher F, Linkesch W, Neumeister P (2013) Brentuximab vedotin is an effective treatment of classical hodgkin lymphoma type post-transplant lymphoproliferative disorder (ptld). Haematologica 98:572\u2013572","journal-title":"Haematologica"},{"issue":"12","key":"5446_CR16","doi-asserted-by":"publisher","first-page":"E153","DOI":"10.1111\/ijd.14214","volume":"57","author":"J Canueto","year":"2018","unstructured":"Canueto J, Ocio EM, Roman-Curto C (2018) Aggressive primary cutaneous CD30+lymphoproliferative disorder in an organ transplant recipient in sustained complete remission with brentuximab vedotin. Int J Dermatol 57(12):E153\u2013E155","journal-title":"Int J Dermatol"},{"issue":"2","key":"5446_CR17","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1177\/1078155220946462","volume":"27","author":"AK Gunes","year":"2021","unstructured":"Gunes AK, Demir I, Pehlivan M (2021) Classical Hodgkin lymphoma-like post-transplant lymphoproliferative disease after allogeneic stem cell transplantation for primary myelofibrosis is successfully treated with nivolumab: a case report. J Oncol Pharm Pract 27(2):509\u2013512","journal-title":"J Oncol Pharm Pract"},{"issue":"5","key":"5446_CR18","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.3109\/10428194.2014.911865","volume":"56","author":"BT Hill","year":"2015","unstructured":"Hill BT, Tubbs RR, Smith MR (2015) Complete remission of CD30-positive diffuse large B-cell lymphoma in a patient with post-transplant lymphoproliferative disorder and end-stage renal disease treated with single-agent brentuximab vedotin. Leuk lymphoma 56(5):1552\u20131553","journal-title":"Leuk lymphoma"},{"issue":"14","key":"5446_CR19","doi-asserted-by":"publisher","first-page":"3493","DOI":"10.1080\/10428194.2021.1957867","volume":"62","author":"WB Pearse","year":"2021","unstructured":"Pearse WB, Petrich AM, Gordon LI, Karmali R, Winter JN, Ma S, Kaplan JB, Behdad A, Klein A, Jovanovic B, Helenowski I, Smith SM, Evens AM, Pro B (2021) A phase I\/II trial of brentuximab vedotin plus rituximab as frontline therapy for patients with immunosuppression-associated CD30+ and\/or EBV + lymphomas. Leuk lymphoma 62(14):3493\u20133500","journal-title":"Leuk lymphoma"},{"issue":"3","key":"5446_CR20","doi-asserted-by":"publisher","first-page":"E8","DOI":"10.1097\/TP.0000000000001099","volume":"100","author":"M Choi","year":"2016","unstructured":"Choi M, Fink S, Prasad V, Anagnostopoulos I, Reinke P, Schmitt CA (2016) T cell PTLD successfully treated with single-agent brentuximab vedotin first-line therapy. Transplantation 100(3):E8\u2013E10","journal-title":"Transplantation"},{"issue":"3","key":"5446_CR21","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1634\/theoncologist.2018-0195","volume":"24","author":"LE Aguirre","year":"2019","unstructured":"Aguirre LE, Guzman ME, Lopes G, Hurley J (2019) Immune checkpoint inhibitors and the risk of allograft rejection: a comprehensive analysis on an emerging issue. Oncologist 24(3):394\u2013401","journal-title":"Oncologist"},{"issue":"21","key":"5446_CR22","doi-asserted-by":"publisher","first-page":"5579","DOI":"10.1158\/1078-0432.CCR-20-1215","volume":"26","author":"F Janku","year":"2020","unstructured":"Janku F, Park H, Call SG, Madwani K, Oki Y, Subbiah V, Hong DS, Naing A, Velez-Bravo VM, Barnes TG, Hagemeister FB, Falchook GS, Karp DD, Wheler JJ, Piha-Paul SA, Garrido-Laguna I, Shpall EJ, Fayad LE, Neelapu SS, Meric-Bernstam F, Kurzrock R, Fanale MA (2020) Safety and efficacy of vorinostat plus sirolimus or everolimus in patients with relapsed refractory Hodgkin lymphoma. Clin Cancer Res 26(21):5579\u20135587","journal-title":"Clin Cancer Res"},{"issue":"7","key":"5446_CR23","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1007\/s00467-013-2505-9","volume":"29","author":"L Pape","year":"2014","unstructured":"Pape L, Ahlenstiel T (2014) mTOR inhibitors in pediatric kidney transplantation. Pediatr Nephrol 29(7):1119\u20131129","journal-title":"Pediatr Nephrol"},{"issue":"9","key":"5446_CR24","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1093\/ckj\/sfaa262","volume":"14","author":"MG Naik","year":"2021","unstructured":"Naik MG, Arns W, Budde K, Diekmann F, Eitner F, Gwinner W, Heyne N, J\u00fcrgensen JS, Morath C, Riester U, Heller KM, Fischereder M (2021) Sirolimus in renal transplant recipients with malignancies in Germany. Clin Kidney J 14(9):2047\u20132058","journal-title":"Clin Kidney J"},{"issue":"2","key":"5446_CR25","doi-asserted-by":"publisher","first-page":"e13464","DOI":"10.1111\/ctr.13464","volume":"33","author":"H Tedesco-Silva","year":"2019","unstructured":"Tedesco-Silva H, Del Carmen Rial M, Cruz Santiago J, Mazzali M, Pacheco-Silva A, Torres R (2019) Optimizing the clinical utility of sirolimus-based immunosuppression for kidney transplantation. Clin Trans 33(2):e13464","journal-title":"Clin Trans"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05446-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-023-05446-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05446-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T16:02:54Z","timestamp":1720108974000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-023-05446-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,26]]},"references-count":25,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["5446"],"URL":"https:\/\/doi.org\/10.1007\/s00277-023-05446-5","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,26]]},"assertion":[{"value":"1 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The studies involving human participants were reviewed and approved by the Ethical Review Committee of Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent has been obtained from the patient to publish this paper.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent statement"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}